Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
Sponsor: GC Biopharma Corp
Summary
This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up to 10 years to monitor varicella infection.
Official title: A Phase III, Double-blind, Randomized, Multicenter, Multinational, Active-controlled, Non-inferiority Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
Key Details
Gender
All
Age Range
12 Months - 12 Years
Study Type
INTERVENTIONAL
Enrollment
474
Start Date
2026-03
Completion Date
2036-07
Last Updated
2025-07-11
Healthy Volunteers
Yes
Conditions
Interventions
MG1111 (Barycela inj.)
MG1111 (Barycela inj.)
VARIVAX™
Varivax™